Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

February 5, 2015

Primary Completion Date

July 22, 2019

Study Completion Date

July 22, 2019

Conditions
Hormone-refractory Prostate Cancer
Interventions
DRUG

Enzalutamide

Enzalutamide 160 mg/day

Trial Locations (16)

14004

Complejo Hospitalario Regional Reina Sofía, Córdoba

24080

Complejo Asistencial Universitario de Leon, León

27003

Hospital Universitario Lucus Augusti, Lugo

28034

Hospital Ramón Y Cajal, Madrid

28040

Hospital Clínico San Carlos, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

29010

Complejo Hospitalario de Especialidades Virgen de La Victoria, Málaga

30008

Hospital General Universitario J.M. Morales Meseguer, Murcia

32005

Complexo Hospitalario Universitario de Ourense, Ourense

41013

Complejo Hospitalario Regional Virgen Del Rocio, Seville

46009

Fundación Instituto Valenciano de Oncologia, Valencia

50009

Hospital Universitario Miguel Servet, Zaragoza

07120

Hospital Universitari Son Espases, Palma de Mallorca

08916

Hospital Universitari Germans Trias I Pujol de Badalona, Badalona

08036

Hospital Clinic I Provincial de Barcelona, Barcelona

Unknown

Hospital Parc Taulí, Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

collaborator

Apices Soluciones S.L.

INDUSTRY

lead

Spanish Oncology Genito-Urinary Group

OTHER

NCT02288936 - Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter